Regulated information
Nazareth (Belgium)/Rotterdam (The Netherlands), 17 October 2025 – 6PM CET
Fagron’s share buy-back program: Weekly update
In the period from 16 October 2025 through 17 October 2025, Fagron purchased 20,000 of its owns shares at an average price of € 20.609 per share corresponding to a total amount of € 412,180.00.
These purchases are part of the share buy-back program of up to 200,000 Fagron shares to fulfill Fagron’s obligations under its long-term incentive scheme, which was announced on 9 October 2025.
The total number of own shares purchased to date is 20,000.
More information, including a detailed overview of the purchase transactions under this program, is available on our share buy-back webpage.
Financial calendar
12 February 2026 Full year results 2025
9 April 2026 Trading update first quarter 2026
30 July 2026 Half year results 2026
Further information
Ignacio Artola
Global Investor Relations Leader
Ignacio.artola@fagron.com
About Fagron
Fagron is a leading global company active in pharmaceutical compounding, focusing on delivering personalized medicine to hospitals, pharmacies, clinics, and patients in more than 30 countries around the world.
Belgian company Fagron NV has its registered office in Nazareth and is listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol ‘FAGR’. Fagron’s operational activities are managed by the Dutch company Fagron BV, which is headquartered in Rotterdam.
Important information regarding forward-looking statements
Certain statements in this press release may be deemed to be forward-looking. Such forward-looking statements are based on current expectations and are influenced by various risks and uncertainties. Consequently, Fagron cannot provide any guarantee that such forward-looking statements will, in fact, materialize and cannot accept any obligation to update or revise any forward-looking statement as a result of new information, future events or for any other reason.
In the event of differences between the English translation and the Dutch original of this press release, the latter prevails.
Attachment
